ArticleFrontiers in neurology
Association of elevated circulating GDF15 and risk in acute retinal artery occlusion.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to investigate the association between circulating growth differentiation factor-15 (GDF15) levels and retinal artery occlusion (RAO), and to assess the diagnostic performance of GDF15 for discriminating RAO patients from controls. Materials and methods: In this cross-sectional study, we quantified serum GDF15 levels using enzyme-linked immunosorbent assay (ELISA). After performing propensity score matching with age and sex adjustment, we conducted univariate and multivariate analyses to describe RAO risk factors. Subsequently, multivariable logistic regression combined with restricted cubic spline analysis was performed to assess the significance of GDF15 in RAO risk evaluation. Results: The results showed that GDF15 levels in patient was significantly increased in serum (median: 587.89 pg./mL vs. 331.54 pg./mL, Conclusion: Our findings indicate that elevated GDF15 levels are significantly associated with the incidence of RAO. GDF15 exhibited acceptable diagnostic accuracy as a single marker, and the inclusion of GDF15 in a multiparameter diagnostic model significantly improved discrimination, highlighting its potential as a biomarker for RAO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.